Gestodene: A review of its pharmacology, potency and tolerability in combined contraceptive preparations

Contraception

Volumn 89, Issue 4, 2014, Pages 242-252

  Stanczyk, Frank Z ^a   Archer, David F ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

Combined oral contraceptives; Ethinyl estradiol; Gestodene; Pharmacology; Review

Indexed keywords

CYPROTERONE ACETATE PLUS ETHINYLESTRADIOL; DESOGESTREL; DESOGESTREL PLUS ETHINYLESTRADIOL; DROSPIRENONE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS GESTODENE; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; GESTODENE; LEVONORGESTREL; NORGESTIMATE; ORAL CONTRACEPTIVE AGENT; GESTAGEN; PREGNANE DERIVATIVE;

ACNE; BLEEDING; BREAST CANCER; BREAST TENSION; CARCINOMA IN SITU; CEREBROVASCULAR ACCIDENT; CONTRACEPTION; DEPRESSION; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DYSMENORRHEA; ENDOMETRIUM CANCER; FEMALE SEXUAL DYSFUNCTION; HEADACHE; HEART INFARCTION; HUMAN; METRORRHAGIA; OVARY CANCER; PATIENT COMPLIANCE; REVIEW; RISK REDUCTION; SIDE EFFECT; SPOTTING; SYSTOLIC BLOOD PRESSURE; THROMBOEMBOLISM; UTERINE CERVIX CANCER; UTERINE CERVIX DYSPLASIA; VENOUS THROMBOEMBOLISM; WITHDRAWAL BLEEDING; DRUG EFFECTS; DRUG INTERACTION; FEMALE; MENSTRUAL CYCLE;

CONTRACEPTIVES, ORAL, COMBINED; DRUG INTERACTIONS; FEMALE; HUMANS; MENSTRUAL CYCLE; NORPREGNENES; PROGESTINS;

EID: 84897111485     PISSN: 00107824     EISSN: 18790518     Source Type: Journal    
DOI: 10.1016/j.contraception.2013.12.003     Document Type: Review

References (97)

1. UN Department of Economic and Social Affairs Population Division. World contraceptive use 2012 [cited Last accessed: 5 December 2012.].
2. I. Wiegratz, and C.J. Thaler Hormonal contraception-what kind, when, and for whom? Dtsch Arztebl Int 108 28-29 2011 495 506
3. P.D. Darney The androgenicity of progestins Am J Med 98 1A 1995 104S 110S
4. Effect of different progestogens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception Lancet 346 8990 1995 1582 1588
5. K.W. Bloemenkamp, F.R. Rosendaal, F.M. Helmerhorst, H.R. Buller, and J.P. Vandenbroucke Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen Lancet 346 8990 1995 1593 1596
6. H. Jick, S.S. Jick, V. Gurewich, M.W. Myers, and C. Vasilakis Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components Lancet 346 8990 1995 1589 1593
7. W.O. Spitzer, M.A. Lewis, L.A. Heinemann, M. Thorogood, and K.D. MacRae Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women BMJ 312 7023 1996 83 88
8. M.L. Regester, and J. Larkin Risk issues and crisis management: a casebook of best practice 2005 Kogan Page Publishers London
9. A.N. Poindexter Third-generation oral contraceptives and thromboembolism risk Obstet Gynecol 89 6 1997 1028 1030
10. B. Dusterberg, S. Beier, W.H.F. Schneider, J. Spona, and M. Breckwoldt Pharmacological features of gestodene in laboratory animals and man M. Breckwoldt, B. Dusterberg, Gestodene: A New Direction in Oral Contraception 1988 Parthenon Publishing Carnforth, Lancs, England 13 29
11. H. Kuhl Pharmacology of estrogens and progestogens: influence of different routes of administration Climacteric 8 Suppl. 1 2005 3 63
12. D. Philibert, F. Bouchoux, M. Degryse, D. Lecaque, F. Petit, and M. Gaillard The pharmacological profile of a novel norpregnance progestin (trimegestone) Gynecol Endocrinol 13 5 1999 316 326
13. F.Z. Stanczyk, J.P. Hapgood, S. Winer Jr., and D.R. Mishell Jr. Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects Endocr Rev 34 2013 171 208
14. J. Spona, and J. Huber Efficacy of low-dose oral contraceptives containing levonorgestrel, gestoden and cyproterone acetate Gynecol Obstet Invest 23 3 1987 184 193
15. U. Gaspard Progestogens in contraception: third-generation pills D.R. Mishell Jr. R. Sitruk-Ware, Progestins and anti-progestins in clinical practice 2000 Marcel Dekker, Inc New York 179 215
16. F.P. Guengerich Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene Chem Res Toxicol 3 4 1990 363 371
17. H. Kuhl Comparative pharmacology of newer progestogens Drugs 51 2 1996 188 215
18. B. Dusterberg, J.-W. Tack, W. Krause, and M. Humpel Pharmacokinetics and biotransformation of gestodene in man M. Elstein, Gestodene: development of a new gestodene-containing low-dose oral contraceptive 1987 Parthenon London 35 44
19. U. Tauber, W. Kuhnz, and M. Humpel Pharmacokinetics of gestodene and ethinyl estradiol after oral administration of a monophasic contraceptive Am J Obstet Gynecol 163 4 Pt 2 1990 1414
20. U. Tauber, J.W. Tack, and H. Matthes Single dose pharmacokinetics of gestodene in women after intravenous and oral administration Contraception 40 4 1989 461 479
21. M. Orme, D.J. Back, S. Ward, and S. Green The pharmacokinetics of ethynylestradiol in the presence and absence of gestodene and desogestrel Contraception 43 4 1991 305 316
22. H. Kuhl, C. Jung-Hoffmann, and F. Heidt Alterations in the serum levels of gestodene and SHBG during 12 cycles of treatment with 30 micrograms ethinylestradiol and 75 micrograms gestodene Contraception 38 4 1988 477 486
23. K. Fotherby Potency and pharmacokinetics of gestagens Contraception 41 5 1990 533 550
24. J. Dinger, T.D. Minh, N. Buttmann, and K. Bardenheuer Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen Obstet Gynecol 117 1 2011 33 40
25. M.I. Wilde, and J.A. Balfour Gestodene. A review of its pharmacology, efficacy and tolerability in combined contraceptive preparations Drugs 50 2 1995 364 395
26. I.F. Godsland, D. Crook, R. Simpson, T. Proudler, C. Felton, and B. Lees et al. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism N Engl J Med 323 20 1990 1375 1381
27. V.T. Miller Lipids, lipoproteins, women and cardiovascular disease Atherosclerosis 108 Suppl. 1994 S73 S82
28. P.G. Yancey, A.E. Bortnick, G. Kellner-Weibel, M. de la Llera-Moya, M.C. Phillips, and G.H. Rothblat Importance of different pathways of cellular cholesterol efflux Arterioscler Thromb Vasc Biol 23 5 2003 712 719
29. K. Fotherby, and A.D. Caldwell New progestogens in oral contraception Contraception 49 1 1994 1 32
30. R. Yildizhan, B. Yildizhan, E. Adali, P. Yoruk, F. Birol, and N. Suer Effects of two combined oral contraceptives containing ethinyl estradiol 30 microg combined with either gestodene or drospirenone on hemostatic parameters, lipid profiles and blood pressure Arch Gynecol Obstet 280 2 2009 255 261
31. L. Speroff, and A. DeCherney Evaluation of a new generation of oral contraceptives. The Advisory Board for the New Progestins Obstet Gynecol. 81 6 1993 1034 1047
32. D. Shoupe New progestins-clinical experiences: gestodene Am J Obstet Gynecol 170 5 Pt 2 1994 1562 1568
33. U.H. Winkler, U. Gaspard, and F. Leidenberger The influence of a low-dose oral contraceptive containing 20mcg ethinylestradiol and 75mcg gestodene on lipid and carbohydrate metabolism P. Lopes, S.R. Killick, The new option in low-dose oral contraception - expanding the gestodene choice 1995 The Parthenon Publishing Group Limited Carnforth, Lancs, England
34. T. Rabe, B. Runnebaum, M. Kohlmeier, J. Harenberg, and H. Weicker Clinical and metabolic effects of gestodene and levonorgestrel Int J Fertil 32 Suppl. 1987 29 44
35. I. Wiegratz, C. Jung-Hoffmann, W. Gross, and H. Kuhl Effect of two oral contraceptives containing ethinyl estradiol and gestodene or norgestimate on different lipid and lipoprotein parameters Contraception 58 2 1998 83 91
36. H. Kuhl, W. Marz, C. Jung-Hoffmann, F. Heidt, and W. Gross Time-dependent alterations in lipid metabolism during treatment with low-dose oral contraceptives Am J Obstet Gynecol 163 1 Pt 2 1990 363 369
37. S.O. Skouby, O. Andersen, K.R. Petersen, L. Molsted-Pedersen, and C. Kuhl Mechanism of action of oral contraceptives on carbohydrate metabolism at the cellular level Am J Obstet Gynecol 163 1 Pt 2 1990 343 348
38. I.F. Godsland, C. Walton, C. Felton, A. Proudler, A. Patel, and V. Wynn Insulin resistance, secretion, and metabolism in users of oral contraceptives J Clin Endocrinol Metab 74 1 1992 64 70
39. F. Ludicke, U.J. Gaspard, F. Demeyer, A. Scheen, and P. Lefebvre Randomized controlled study of the influence of two low estrogen dose oral contraceptives containing gestodene or desogestrel on carbohydrate metabolism Contraception 66 6 2002 411 415
40. U.J. Gaspard, and P.J. Lefebvre Clinical aspects of the relationship between oral contraceptives, abnormalities in carbohydrate metabolism, and the development of cardiovascular disease Am J Obstet Gynecol 163 1 Pt 2 1990 334 343
41. W.N. Spellacy, A.M. Tsibris, J.C. Tsibris, S. George, R.A. Chez, and W.F. O'Brien Carbohydrate metabolism studies after one year of using an oral contraceptive containing gestodene and ethinyl estradiol Contraception 49 2 1994 125 130
42. H. Cohen, I.J. Mackie, K. Walshe, M.D. Gillmer, and S.J. Machin A comparison of the effects of two triphasic oral contraceptives on haemostasis Br J Haematol 69 2 1988 259 263
43. M.J. Ball, E. Ashwell, M. Jackson, and M.D. Gillmer Comparison of two triphasic contraceptives with different progestogens: effects on metabolism and coagulation proteins Contraception 41 4 1990 363 376
44. R.N. Prasad, S.C. Koh, O.A. Viegas, and S.S. Ratnam Effects on hemostasis after two-year use of low dose combined oral contraceptives with gestodene or levonorgestrel Clin Appl Thromb Hemost 5 1 1999 60 70
45. H. Refn, A. Kjaer, A.M. Lebech, B. Borggaard, L. Schierup, and A. Bremmelgaard Metabolic changes during treatment with two different progestogens Am J Obstet Gynecol 163 1 Pt 2 1990 374 377
46. U.H. Winkler, A.E. Schindler, J. Endrikat, and B. Dusterberg A comparative study of the effects of the hemostatic system of two monophasic gestodene oral contraceptives containing 20 micrograms and 30 micrograms ethinylestradiol Contraception 53 2 1996 75 84
47. O. Lidegaard, E. Lokkegaard, A. Jensen, C.W. Skovlund, and N. Keiding Thrombotic stroke and myocardial infarction with hormonal contraception N Engl J Med 366 24 2012 2257 2266
48. O. Lidegaard, L.H. Nielsen, C.W. Skovlund, F.E. Skjeldestad, and E. Lokkegaard Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9 BMJ 343 2011 d6423
49. L.A. Heinemann, J.C. Dinger, A. Assmann, and T.D. Minh Use of oral contraceptives containing gestodene and risk of venous thromboembolism: outlook 10 years after the third-generation pill scare Contraception 81 5 2010 401 407
50. J. Dinger, and S. Shapiro Combined oral contraceptives, venous thromboembolism, and the problem of interpreting large but incomplete datasets J Fam Plann Reprod Health Care 38 1 2012 2 6
51. J. Dinger, A. Assmann, S. Mohner, and T.D. Minh Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study J Fam Plann Reprod Health Care 36 3 2010 123 129
52. S.L. Liu, and C.M. Lebrun Effect of oral contraceptives and hormone replacement therapy on bone mineral density in premenopausal and perimenopausal women: a systematic review Br J Sports Med 40 1 2006 11 24
53. J. Balasch Sex steroids and bone: current perspectives Hum Reprod Update 9 3 2003 207 222
54. E.F. Eriksen, D.S. Colvard, N.J. Berg, M.L. Graham, K.G. Mann, and T.C. Spelsberg et al. Evidence of estrogen receptors in normal human osteoblast-like cells Science 241 4861 1988 84 86
55. M.J. Oursler, P. Osdoby, J. Pyfferoen, B.L. Riggs, and T.C. Spelsberg Avian osteoclasts as estrogen target cells Proc Natl Acad Sci U S A 88 15 1991 6613 6617
56. C. Nappi, Sardo A. Di Spiezio, E. Greco, G.A. Tommaselli, E. Giordano, and M. Guida Effects of an oral contraceptive containing drospirenone on bone turnover and bone mineral density Obstet Gynecol 105 1 2005 53 60
57. A.M. Paoletti, M. Orru, S. Floris, M. Mannias, A.M. Vacca, and S. Ajossa et al. Evidence that treatment with monophasic oral contraceptive formulations containing ethinylestradiol plus gestodene reduces bone resorption in young women Contraception 61 4 2000 259 263
58. C. Nappi, Sardo A. Di Spiezio, G. Acunzo, G. Bifulco, G.A. Tommaselli, and M. Guida et al. Effects of a low-dose and ultra-low-dose combined oral contraceptive use on bone turnover and bone mineral density in young fertile women: a prospective controlled randomized study Contraception 67 5 2003 355 359
59. S. Caruso, C. Agnello, G. Intelisano, M. Farina, L. Di Mari, and A. Cianci Sexual behavior of women taking low-dose oral contraceptive containing 15 microg ethinylestradiol/60 microg gestodene Contraception 69 3 2004 237 240
60. C. Panzer, S. Wise, G. Fantini, D. Kang, R. Munarriz, and A. Guay et al. Impact of oral contraceptives on sex hormone-binding globulin and androgen levels: a retrospective study in women with sexual dysfunction J Sex Med 3 1 2006 104
61. S. Oranratanaphan, and S. Taneepanichskul A double blind randomized control trial, comparing effect of drospirenone and gestodene to sexual desire and libido J Med Assoc Thai 89 Suppl. 4 2006 S17 S22
62. J. Bancroft, D.W. Davidson, P. Warner, and G. Tyrer Androgens and sexual behaviour in women using oral contraceptives Clin Endocrinol (Oxf) 12 4 1980 327 340
63. M. Dei, A. Verni, L. Bigozzi, and V. Bruni Sex steroids and libido Eur J Contracept Reprod Health Care 2 4 1997 253 258
64. S.R. Davis, S.L. Davison, S. Donath, and R.J. Bell Circulating androgen levels and self-reported sexual function in women JAMA 294 1 2005 91 96
65. J. Trussell, and D. Portman The creeping pearl: why has the rate of contraceptive failure increased in clinical trials of combined hormonal contraceptive pills? Contraception 88 5 2013 604 610
66. A.B. Edelman, N.E. Carlson, G. Cherala, M.Y. Munar, R.L. Stouffer, and J.L. Cameron et al. Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity Contraception 80 2 2009 119 127
67. C.L. Westhoff, A.H. Torgal, E.R. Mayeda, K. Petrie, T. Thomas, and M. Dragoman et al. Pharmacokinetics and ovarian suppression during use of a contraceptive vaginal ring in normal-weight and obese women Am J Obstet Gynecol 207 1 2012 39 e1-6
68. Westhoff C, Reinecke I, Bangerter K, Merz M. Impact of body mass index on suppression of follicular development and ovulation using a transdermal patch containing 0.55 mg ethinyl estradiol/2.1 mg gestodene: a multicenter, open-label, uncontrolled study over three treatment cycles. Manuscript in preparation. 2013.
69. C.L. Westhoff, A.T. Torgal, E.R. Mayeda, N. Shimoni, F.Z. Stanczyk, and M.C. Pike Predictors of noncompliance in an oral contraceptive clinical trial Contraception 85 5 2012 465 469
70. K. Brill, T. Norpoth, J. Schnitker, and M. Albring Clinical experience with a modern low-dose oral contraceptive in almost 100,000 users Contraception 43 2 1991 101 110
71. F. Weber-Diehl, R. Unger, and U. Lachnit Triphasic combination of ethinyl estradiol and gestodene. Long-term clinical trial Contraception 46 1 1992 19 27
72. P. Affinito, M. Monterubbianesi, M. Primizia, V. Regine, C. Di Carlo, and M.J. Farace et al. Efficacy, cycle control and side-effects of two monophasic combination oral contraceptives: gestodene/ethinylestradiol and norgestimate/ethinylestradiol Gynecol Endocrinol 7 4 1993 259 266
73. R.J. Kirkman, J.H. Pedersen, P. Fioretti, and H.E. Roberts Clinical comparison of two low-dose oral contraceptives, Minulet and Mercilon, in women over 30 years of age Contraception 49 1 1994 33 46
74. N.B. Loudon, R.J. Kirkman, and J.A. Dewsbury A double-blind comparison of the efficacy and acceptability of Femodene and Microgynon-30 Eur J Obstet Gynecol Reprod Biol 34 3 1990 257 266
75. F. Weber-Diehl, J. Lehnert, and U. Lachnit Comparison of two triphasic oral contraceptives containing either gestodene or norethindrone: a randomized, controlled trial Contraception 48 4 1993 291 301
76. D.F. Archer, S.T. Nakajima, A.T. Sawyer, J. Wentworth, S. Trupin, and W.D. Koltun et al. Norethindrone acetate 1.0 milligram and ethinyl estradiol 10 micrograms as an ultra low-dose oral contraceptive Obst Gynecol 122 3 2013 601 607
77. S.T. Nakajima, D.F. Archer, and H. Ellman Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 micro g (Loestrin 24 Fe) Contraception 75 1 2007 16 22
78. D.F. Archer Vascular dysfunction as a cause of endometrial bleeding Gynecol Endocrinol 28 9 2012 688 693
79. M.J. Rosenberg, M.S. Waugh, and J.E. Higgins The effect of desogestrel, gestodene, and other factors on spotting and bleeding Contraception 53 2 1996 85 90
80. A. Kubba, and J. Guillebaud Combined oral contraceptives: acceptability and effective use Br Med Bull 49 1 1993 140 157
81. M. Nichols, G. Robinson, W. Bounds, B. Newman, and J. Guillebaud Effect of four combined oral contraceptives on blood pressure in the pill-free interval Contraception 47 4 1993 367 376
82. R.D. Farmer, R.A. Lawrenson, J.C. Todd, T.J. Williams, K.D. MacRae, and F. Tyrer et al. A comparison of the risks of venous thromboembolic disease in association with different combined oral contraceptives Br J Clin Pharmacol 49 6 2000 580 590
83. L.A. Heinemann, and J.C. Dinger Range of published estimates of venous thromboembolism incidence in young women Contraception 75 5 2007 328 336
84. F. Fruzzetti, C. Ricci, and P. Fioretti Haemostasis profile in smoking and nonsmoking women taking low-dose oral contraceptives Contraception 49 6 1994 579 592
85. S. Suissa, W.O. Spitzer, B. Rainville, J. Cusson, M. Lewis, and L. Heinemann Recurrent use of newer oral contraceptives and the risk of venous thromboembolism Hum Reprod 15 4 2000 817 821
86. W.H. Catherino, M.H. Jeng, and V.C. Jordan Norgestrel and gestodene stimulate breast cancer cell growth through an oestrogen receptor mediated mechanism Br J Cancer 67 5 1993 945 952
87. B. van der Burg, E. Kalkhoven, L. Isbrucker, and S.W. de Laat Effects of progestins on the proliferation of estrogen-dependent human breast cancer cells under growth factor-defined conditions J Steroid Biochem Mol Biol 42 5 1992 457 465
88. B.L. Strom, J.A. Berlin, A.L. Weber, S.A. Norman, L. Bernstein, and R.T. Burkman et al. Absence of an effect of injectable and implantable progestin-only contraceptives on subsequent risk of breast cancer Contraception 69 5 2004 353 360
89. C.I. Li, E.F. Beaber, M.T. Tang, P.L. Porter, J.R. Daling, and K.E. Malone Effect of depo-medroxyprogesterone acetate on breast cancer risk among women 20 to 44 years of age Cancer Res 72 8 2012 2028 2035
90. P. Hannaford Health consequences of combined oral contraceptives Br Med Bull 56 3 2000 749 760
91. V. Moreno, F.X. Bosch, N. Munoz, C.J. Meijer, K.V. Shah, and J.M. Walboomers et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study Lancet 359 9312 2002 1085 1092
92. M.P. Vessey, and R. Painter Endometrial and ovarian cancer and oral contraceptives-findings in a large cohort study Br J Cancer 71 6 1995 1340 1342
93. D.J. Back, R. Houlgrave, J.F. Tjia, S. Ward, and M.L. Orme Effect of the progestogens, gestodene, 3-keto desogestrel, levonorgestrel, norethisterone and norgestimate on the oxidation of ethinyloestradiol and other substrates by human liver microsomes J Steroid Biochem Mol Biol 38 2 1991 219 225
94. F.Z. Stanczyk Pharmacokinetics of the new progestogens and influence of gestodene and desogestrel on ethinylestradiol metabolism Contraception 55 5 1997 273 282
95. S. Palovaara, K.T. Kivisto, P. Tapanainen, P. Manninen, P.J. Neuvonen, and K. Laine Effect of an oral contraceptive preparation containing ethinylestradiol and gestodene on CYP3A4 activity as measured by midazolam 1′-hydroxylation Br J Clin Pharmacol 50 4 2000 333 337
96. E.E. Jones Androgenic effects of oral contraceptives: implications for patient compliance Am J Med 98 1A 1995 116S 119S
97. O. Lidegaard, E. Lokkegaard, A.L. Svendsen, and C. Agger Hormonal contraception and risk of venous thromboembolism: national follow-up study BMJ 339 2009 b2890